STOCK TITAN

Ideaya Biosciences Inc - IDYA STOCK NEWS

Welcome to our dedicated news page for Ideaya Biosciences (Ticker: IDYA), a resource for investors and traders seeking the latest updates and insights on Ideaya Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ideaya Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ideaya Biosciences's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.73%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.2%
Tags
-
Rhea-AI Summary
IDEAYA Biosciences provided a business update and announced financial results for Q1 2023. The company reported a strong balance sheet and estimated net proceeds from a public offering. They also provided updates on their clinical programs, including the initiation of a Phase 2/3 trial for darovasertib and crizotinib combination in MUM. IDEAYA reported compelling clinical efficacy for darovasertib and plans to submit IND for Pol Theta Helicase DC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.62%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.97%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.62%
Tags
none
Rhea-AI Summary
IDEAYA Biosciences, Inc. has closed its underwritten public offering, raising approximately $201 million. The offering consisted of 8,858,121 shares of common stock and pre-funded warrants to purchase 2,020,270 shares of common stock. The underwriters also exercised their option to purchase an additional 1,418,920 shares. J.P. Morgan, Jefferies, and Citigroup acted as joint book-running managers for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.62%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8%
Tags
Ideaya Biosciences Inc

Nasdaq:IDYA

IDYA Rankings

IDYA Stock Data

3.13B
73.78M
0.98%
102.9%
12.62%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
South San Francisco

About IDYA

ideaya biosciences is an oncology-focused biotechnology company committed to the discovery of personalized synthetic lethality medicines targeting dna damage and repair for genetically defined patient populations and immuno-oncology therapies targeting the tumor microenvironment. founded in 2015, ideaya’s investors include 5am ventures (5am), canaan partners (canaan), celgene, wuxi healthcare ventures (wuxi), novartis institute of biomedical research, and alexandria real estate. the company has assembled a world-class drug discovery team and scientific advisory board (sab) that is represented by a nobel laureate and three members of the national academy of sciences. ideaya is located in south san francisco and la jolla, california.